PD-1-directed CAR T cells

PD-1-directed CAR T cells are chimeric antigen receptor (CAR) T cells engineered to target and deplete pathogenic PD-1-expressing T cells, specifically PD-1⁺ CD4⁺ T follicular helper-like cells. Developed by researchers at the Weizmann Institute of Science, Tel Aviv University, and Rabin Medical Center, these CAR T cells are designed to treat neuroinflammatory and autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). In armored versions, the CAR T cells are engineered to locally release interleukin-10 (IL-10) or soluble TNF receptor II (sTNFRII) at inflammatory sites, which helps attenuate inflammation, reprogram the local immune microenvironment, and promote tissue repair.

Other names

PD-1-directed CAR-T cellsPD1-directed CAR-T cellsPD 1-directed CAR-T cellsPD-1-targeted CAR T cellsPD1-targeted CAR T cellsPD 1-targeted CAR T cellsPD-1-targeted CAR-T cellsPD1-targeted CAR-T cellsPD 1-targeted CAR-T cells